Philadelphia retains top 30 ranking on list of global startup ecosystems in 2023
In 2022, Startup Genome's Global Startup Ecosystem Report ranked Philadelphia as the 27th-best startup ecosystem in the world and number eleven within the U.S.
Penn Startups Win Several PACT Enterprise Awards
viTToria Biotherapeutics and Exyn Technologies, both startups co-founded by Penn faculty, won recent awards from the Philadelphia Alliance for Capital and Technologies.
Cabaletta Bio Receives FDA Fast Track Designation for CABA-201 Drug to Target Autoimmune Diseases
Cabaletta Bio received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its drug CABA-201.
Verismo Therapeutics Activates its STAR-101 Clinical Trial to Evaluate Investigational Drug SynKIR-110
Penn spinout Verismo Therapeutics, which focuses on CAR T-cell therapy for solid tumors, has activated its STAR-101 Phase 1 clinical trial at Penn.
PCI’s Carter Caldwell Is Interviewed on Launching a Startup
PCI’s Carter Caldwell, program director for the Penn Medicine Co-Investment Program, discussed his entrepreneurial career and shared advice for others looking to start businesses.
SAFELab takes space at Pennovation Center
SAFELab is a research initiative focused on examining the ways in which youth of color navigate violence on and offline.
Philadelphia Business Journal Features Liz Magill and her Innovation Goals
In an interview about her long-term vision for the university with the Philadelphia Business Journal, Penn President Liz Magill mentions Penn’s breakthroughs in cell and gene therapy.
Philadelphia ranks as one of the top five most active regions for venture capital in 1Q
According to the latest Pitchbook-NVCA Venture Monitor report, the Greater Philadelphia area ranked fifth in the U.S. for the most closed venture capital deals in 2022 and the start of 2023.
REGENXBIO Receives FDA Fast Track Designation for its Novel Gene Therapy Candidate
Penn spinout REGENXBIO received FDA Fast Track designation for its novel gene therapy candidate RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne muscular dystrophy.
PCI Promotes Innovation and Startups at the South by Southwest (SXSW) annual Interactive Conference
It was a great opportunity to share the innovation initiatives coming out of Penn and Philadelphia with a global audience.